Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.

Solomon DH, Shadick NA, Weinblatt ME, Zak A, Frits M, Franklin JM.

Arthritis Res Ther. 2017 Jun 13;19(1):130. doi: 10.1186/s13075-017-1330-0.

2.

Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.

Mori S, Yoshitama T, Hidaka T, Sakai F, Hasegawa M, Hashiba Y, Suematsu E, Tatsukawa H, Mizokami A, Yoshizawa S, Hirakata N, Ueki Y.

PLoS One. 2017 Jun 8;12(6):e0179179. doi: 10.1371/journal.pone.0179179. eCollection 2017.

3.

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.

Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, Dimonaco S, Rubbert-Roth A, van Vollenhoven R, Genovese MC.

Rheumatology (Oxford). 2017 Apr 1;56(4):541-549. doi: 10.1093/rheumatology/kew370. Review.

4.

Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.

Kawashima H, Kagami SI, Kashiwakuma D, Takahashi K, Yokota M, Furuta S, Iwamoto I.

Rheumatol Int. 2017 Mar;37(3):369-376. doi: 10.1007/s00296-016-3631-z. Epub 2016 Dec 20.

6.

Rituximab for Rheumatoid Arthritis.

Cohen MD, Keystone E.

Rheumatol Ther. 2015 Dec;2(2):99-111. Epub 2015 Aug 19. Review.

7.

Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.

Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, Costenbader KH, Kim SC.

Arthritis Rheumatol. 2017 Feb;69(2):387-397. doi: 10.1002/art.39849.

PMID:
27589220
8.

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry.

Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD.

Arthritis Care Res (Hoboken). 2016 Dec;68(12):1888-1893. doi: 10.1002/acr.22912.

9.

An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score.

Desai RJ, Solomon DH, Weinblatt ME, Shadick N, Kim SC.

Arthritis Res Ther. 2015 Apr 13;17:83. doi: 10.1186/s13075-015-0599-0.

10.

TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.

Diogo D, Bastarache L, Liao KP, Graham RR, Fulton RS, Greenberg JD, Eyre S, Bowes J, Cui J, Lee A, Pappas DA, Kremer JM, Barton A, Coenen MJ, Franke B, Kiemeney LA, Mariette X, Richard-Miceli C, Canhão H, Fonseca JE, de Vries N, Tak PP, Crusius JB, Nurmohamed MT, Kurreeman F, Mikuls TR, Okada Y, Stahl EA, Larson DE, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Kosoy R, Ransom M, Bhangale TR, Ortmann W, Cagan A, Gainer V, Karlson EW, Kohane I, Murphy SN, Martin J, Zhernakova A, Klareskog L, Padyukov L, Worthington J, Mardis ER, Seldin MF, Gregersen PK, Behrens T, Raychaudhuri S, Denny JC, Plenge RM.

PLoS One. 2015 Apr 7;10(4):e0122271. doi: 10.1371/journal.pone.0122271. eCollection 2015.

11.

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

Alawneh KM, Ayesh MH, Khassawneh BY, Saadeh SS, Smadi M, Bashaireh K.

Biologics. 2014 Apr 22;8:193-8. doi: 10.2147/BTT.S59574. eCollection 2014.

12.

TNF inhibitor therapy for rheumatoid arthritis.

Ma X, Xu S.

Biomed Rep. 2013 Mar;1(2):177-184. Epub 2012 Nov 29. Review.

13.

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR.

Ann Rheum Dis. 2015 Jun;74(6):1065-71. doi: 10.1136/annrheumdis-2013-204011. Epub 2014 Mar 7.

14.

Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.

Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell E, Saag KG, Safford MM, DuVall S, Alexander K, Napalkov P, Winthrop KL, Burton MJ, Kamauu A, Baddley JW.

Arthritis Care Res (Hoboken). 2014 Jul;66(7):990-7. doi: 10.1002/acr.22281.

15.

Rituximab for the treatment of rheumatoid arthritis: an update.

Mok CC.

Drug Des Devel Ther. 2013 Dec 27;8:87-100. doi: 10.2147/DDDT.S41645. Review.

16.

Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure.

Gutierrez-Gonzalez LA, Gudiño MA, Ceija IO, Leonet MM, Noguera ZT.

Open Rheumatol J. 2013 Oct 18;7:81-6. doi: 10.2174/1874312920130913004. eCollection 2013.

17.

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

Ann Rheum Dis. 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407. Epub 2013 Jul 13.

18.

Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.

Jain A, Singh JA.

Immunotherapy. 2013 Mar;5(3):265-99. doi: 10.2217/imt.13.10. Review.

19.

Combined infliximab and rituximab in necrotising scleritis.

Morarji J, Joshi L, Tomkins-Netzer O, Lightman S, Taylor SR.

Case Rep Ophthalmol. 2012 Sep;3(3):286-90. doi: 10.1159/000342842. Epub 2012 Sep 11.

20.

Development and validation of a risk score for serious infection in patients with rheumatoid arthritis.

Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL.

Arthritis Rheum. 2012 Sep;64(9):2847-55. doi: 10.1002/art.34530.

Supplemental Content

Support Center